Send to

Choose Destination
Future Med Chem. 2016 Jun;8(9):975-92. doi: 10.4155/fmc-2016-0017. Epub 2016 May 26.

Pseudomonas aeruginosa: targeting cell-wall metabolism for new antibacterial discovery and development.

Author information

Department of Biochemistry & Biomedical Sciences & the Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada.


Pseudomonas aeruginosa is a leading cause of hospital-acquired infections and is resistant to most antibiotics. With therapeutic options against P. aeruginosa dwindling, and the lack of new antibiotics in advanced developmental stages, strategies for preserving the effectiveness of current antibiotics are urgently required. β-Lactam antibiotics are important agents for treating P. aeruginosa infections, thus, adjuvants that potentiate the activity of these compounds are desirable for extending their lifespan while new antibiotics - or antibiotic classes - are discovered and developed. In this review, we discuss recent research that has identified exploitable targets of cell-wall metabolism for the design and development of compounds that hinder resistance and potentiate the activity of antipseudomonal β-lactams.


AmpC β-lactamase; antibiotic adjuvant; biofilm; cell-wall metabolism; combination therapy; opportunistic pathogen; β-lactam antibiotics

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center